LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, has added a major talent to its executive suite today by announcing that internationally prominent scientific management, clinical and regulatory expert Daniel Levitt, MD, Ph.D., has joined the company as Chief Medical Officer. This position is pivotal in defining, building and protecting the company’s market franchise, and is therefore instrumental in strengthening stockholder interests. With leadership responsibility over all CytRx drug development programs, Dr. Levitt brings more than 24 years of senior management experience, spearheading numerous drug development programs to commercialization at leading biotechnology and pharmaceutical companies.
